SiRNA, effective for the treatment of Fibrosis and a Pharmaceutical Product containing siRNA.A siRNA which has a full length of 30 or less and that leads to a Nucleotide sequence that consists of 17 to 23 consecutive bases selected from the group consisting of bases AT positions 1285 to 1318, bases AT positions 1398 to 1418, bases AT positions 112 1463, bases In 1548, 1579 positions, positions bases in 1608 to 1628,Bases at positions 1700 to 1726, bases AT positions 1778 to 1798, bases in 1806 to 1826 positions and bases in 1887 and 1907 the positions of SEQ ID no. 1. Small interfering RNA Inhibits the expression of tgf-b1 Gene. Use of siRNA. Method of treatment.Buluş, fibroz için terapötik bir ajan ile ilgilidir. Spesifik olarak, mevcut buluş, dönüştürücü büyüme faktörü (TGF) - ß1 ve siRNA'yı içeren bir farmasötik maddeyi kodlayan bir geni hedef alan küçük engelleyici RNA (siRNA) ile ilgilidir.
